Inhibrx Inc
INBX
Market Cap$1.82B
Close$
$1.31
96.2% downside
Current Fair Value
96.2% downsideOvervalued by 96.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.82 Billion |
|---|---|
| Enterprise Value | $1.78 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-5.44 |
| Beta | 0.0 |
| Outstanding Shares | 52,401,941 |
| Avg 30 Day Volume | 515,613 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -6.71 |
|---|---|
| PEG | -11.01 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 996.5 |
| Enterprise Value to EBIT | -7.13 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.12 |
| Debt to Equity | 18.23 |
Revenue Sources
No data
ESG Score
No data
About Inhibrx Inc
88 employeesInhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the spe...